Cite
HARVARD Citation
Matulonis, U. et al. (n.d.). 949PMirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study. Annals of oncology. p. . [Online].